VSTM insider trading
NasdaqCM HealthcareVerastem, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Company website: www.verastem.com
VSTM insider activity at a glance
FilingIQ has scored 282 insider transactions for VSTM since Dec 23, 2014. The most recent filing in our index is dated May 4, 2026.
Across the full history, 29 open-market purchases
and 154 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on VSTM insider trades is 53.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding VSTM
Frequently asked
- How many insider trades does FilingIQ track for VSTM?
- FilingIQ tracks 282 Form 4 insider transactions for VSTM (Verastem, Inc.), covering filings from Dec 23, 2014 onwards. 2 of those were filed in the last 90 days.
- Are VSTM insiders net buyers or net sellers?
- Across the full Form 4 history for VSTM, 29 transactions (10%) were open-market purchases and 154 (55%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does VSTM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is VSTM in?
- Verastem, Inc. (VSTM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $444.01M.
Methodology & sources
Every VSTM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.